Currently, there are 102.32M common shares owned by the public and among those 86.99M shares have been available to trade.
The company’s stock has a 5-day price change of -19.04% and -61.09% over the past three months. DYN shares are trading -60.82% year to date (YTD), with the 12-month market performance down to -67.49% lower. It has a 12-month low price of $9.96 and touched a high of $47.45 over the same period. DYN has an average intraday trading volume of 2.13 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -21.87%, -29.57%, and -67.51% respectively.
Institutional ownership of Dyne Therapeutics Inc (NASDAQ: DYN) shares accounts for 81.01% of the company’s 102.32M shares outstanding.
It has a market capitalization of $1.04B and a beta (3y monthly) value of 1.21. The earnings-per-share (ttm) stands at -$3.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.23% over the week and 6.78% over the month.
Earnings per share for the fiscal year are expected to decrease by -5.63%, and -3.77% over the next financial year. EPS should grow at an annualized rate of 4.20% over the next five years, compared to -59.45% over the past 5-year period.
Looking at the support for the DYN, a number of firms have released research notes about the stock. BMO Capital Markets stated their Outperform rating for the stock in a research note on March 12, 2025, with the firm’s price target at $50. Scotiabank coverage for the Dyne Therapeutics Inc (DYN) stock in a research note released on March 07, 2025 offered a Sector Outperform rating with a price target of $50. Robert W. Baird was of a view on December 13, 2024 that the stock is Outperform, while RBC Capital Mkts gave the stock Outperform rating on November 26, 2024, issuing a price target of $45. JP Morgan on their part issued Neutral rating on October 24, 2024.
